| abciximab |
GPIIbIIIa/ |
Réopro |
Centocor / Janssen / |
|
CD11b/CD18 |
|
Eli Lilly and Company |
|
αvβ3 |
|
|
| adalimumab |
TNF-α |
Humira |
Cambridge Antibody Technology(CAT) / AbbVie |
| adécatumumab |
EpCAM |
- |
Micromet / Merck |
| aducanumab |
amyloïde β |
- |
Neurimmune / Biogen |
|
(A-β fibrillaire) |
|
|
| ado-trastuzumab emtansine (DM1) |
HER2/neu |
Kadcyla |
Genentech (Roche) / Lonza |
| aérubumab |
Ps°°°° |
Aerucin |
Aridis Pharmaceuticals |
| alemtuzumab |
CD52 |
Lemtrada |
Sanofi Genzyme |
| alirocumab |
PCSK9++
|
Praluent |
Sanofi-Aventis |
| anifrolumab |
IFNAR1 |
- |
Medimmune LLC / AstraZeneca |
| atézolizumab |
PD-L1 |
Tecentriq |
Genentech (Roche+) |
| avélumab |
PD-L1 |
Bavencio |
Merck Sharp & Dohme / Pfizer |
| basiliximab |
IL-2Rα (CD25) |
Simulect |
Novartis |
| bavituximab |
Phosphatidylsérine |
- |
Peregrine Pharmaceuticals |
| bélantamab mafodotine. |
BCMA (TNFRSF17) |
- |
GlaxoSmithKline |
| bélimumab |
BLyS (BAFF) |
Benlysta |
GlaxoSmithKline |
| benralizumab |
IL-5R |
Fasenra |
AstraZeneca |
| bévacizumab |
VEGF-A |
Avastin |
Roche |
| bézlotoxumab |
entérotoxine B |
Zinplava |
Merck Sharp & Dohme |
|
Clostridium difficile
|
|
|
| bimékizumab |
IL-17A/F |
- |
UCB |
| blésélumab |
CD40 |
- |
Kiowa Kirin Pharmaceuticals |
| blinatumomab |
CD3εxCD19 |
Blincyto |
Micromet / Amgen |
| bococizumab |
PCSK9 |
- |
Pfizer |
| brentuximab védotine |
CD30 |
Adcetris |
Seattle Genetics |
| burosumab |
FGF23 |
Crysvita |
Kyowa Hakko Kirin Pharma |
| cabiralizumab |
CSF1-R (CD115) |
- |
Five Prime Therapeutics/ Bristol-Myers Squibb |
| camrélizumab |
PD-1 |
- |
Jiangsu HengRui Medicine |
| canakinumab |
IL-1β |
Ilaris |
Novartis |
| caplacizumab |
vWF |
Cablivi |
Sanofi |
| catumaxomab |
CD3ε x EpCAM |
Removab |
Fresenius Biotech / Trion Pharma |
| cémiplimab |
PD-1 (CD279) |
Libtayo |
Regeneron / Sanofi |
| cergutuzumab amunaleukin |
ACE |
- |
Roche |
| certolizumab pégol |
TNF-α |
Cimzia |
UCB Pharma |
| cétrélimab |
PD-1 (CD279) |
- |
Janssen |
| cétuximab |
EGF-R |
Erbitux |
Imclone / Merck Serono |
| conatumumab |
TRAIL-R2(DR5, APO-2) |
- |
Amgen / Takeda |
| concizumab |
TFPI°°° |
- |
Novo Nordisk |
| cosfroviximab |
Gp surface Ebola virus≠
|
ZMapp |
Mapp Biopharmaceuticals |
| crénézumab |
amyloïde β(A-β fibrillaire) |
- |
Genentech (Roche) |
| cusatuzumab |
CD70 |
- |
Argenx / Janssen Cilag |
| dacétuzumab |
CD40 |
- |
Seattle Genetics / Genentech |
| daclizumab |
CD25 (IL-2Rα) |
Zinbryta |
Protein Design Labs BioPharma / Biogen / AbbVie |
| dapirolizumab pégol |
CD40L (CD154) |
- |
UCB Pharma |
| daratumumab |
CD38 |
Darzalex |
Janssen |
| dénosumab |
RANKL |
Prolia / Xgeva |
Amgen |
| dépatuxizumab madofotine |
EGF-RvIII |
- |
AbbVie |
| dinutuximab bêta |
GD2 |
Qarziba |
EUSA Pharma / Jazz Pharmaceuticals |
| diridavumab |
HA##
|
- |
Janssen |
| drozitumab |
TRAIL-R2(DR5, APO-2) |
- |
Genentech (Roche) |
| dupilumab |
IL-4/IL-13Rα |
Dupixent |
Regeneron / Sanofi |
| durvalumab |
PD-L1 |
Imfinzi |
MedImmune LLC / AstraZeneca |
| éculizumab |
C5 |
Soliris |
Alexion Pharmaceuticals |
| éfalizumab |
CD11a |
Raptiva |
Genentech / Merck Serono |
| éfungumab |
Hsp90≠≠
|
Mycograb |
NeuTec Pharma / Novartis |
| élotuzumab |
SLAMF7 |
Empliciti |
Bristol-Myers Squibb |
| émactuzumab |
CSF1-R (CD115) |
- |
Genentech / Roche |
| émicizumab |
facteurs IXa x X |
Hemlibra |
Chugai (Roche) |
| enfortumab védotin |
nectine 4 |
- |
Seattle Genetics |
| énoblituzumab. |
B7-H3 (CD276) |
- |
MacroGenics |
| eptinézumab |
CGRP$$
|
- |
Alder Biopharmaceuticals |
| érénumab |
CGRP |
Aimovig |
Amgen / Novartis |
| erlizumab |
CD18 |
- |
Genentech (Roche) |
| ertumaxomab |
HER2/neu x CD3εx RFcγI/II/III |
- |
Fresenius Biotech |
| étanercept |
TNF-α |
Enbrel |
Pfizer |
| étigilimab |
TIGIT |
- |
Oncomed / Mereo BioPharma |
| énoblituzumab |
B7-H3 (CD276) |
- |
MacroGenics |
| évolocumab |
PCSK9++
|
Repatha |
Amgen |
| farlétuzumab |
Folate receptor 1 |
- |
Morphotek |
| felvizumab |
F§§(protéine de fusion) |
- |
GlaxoSmithKline |
| flotétuzumab |
CD123 x CD3e |
- |
MacroGenics |
| foravirumab |
gp I et gpIII§§§
|
- |
Crucell / Sanofi Pasteur |
| frémanézumab |
CGRP |
Ajovy |
Teva |
| frésolimumab |
TGF-β |
- |
Genzyme (Sanofi) |
| futuximab |
EGFR (Erb1, HER1) |
- |
Symphogen |
| galcanézumab |
CGRP |
Emgality |
Eli Lilly & Company |
| galiximab |
CD80 |
Biogen (ex-Biogen Idec) |
|
| ganténérumab |
amyloïde β(A-β fibrillaire) |
- |
Roche |
| gédivumab |
HA |
- |
Genentech (Roche) |
| gemtuzumab ozogamicin |
CD33 |
Mylotarg |
Celltech / Wyeth |
| golimumab |
TNF-α |
Simponi |
Janssen |
| grémubamab |
PcrV et PsI++++
|
- |
MedImmune (AstraZeneca) |
| guselkumab |
IL-23Rp19 |
Tremfya |
Janssen |
| ibalizumab |
CD4 |
Trogarzo |
Theratechnologies |
| ibritumomab tiuxetan |
CD20 |
Zevalin |
Spectrum Pharmaceuticals / Acrotech Biopharma |
| idarucizumab |
Dabigatran |
Praxbind |
Boehringer Ingelheim |
| inclacumab |
Sélectine P |
- |
Roche |
| infliximab |
TNF-α |
Remicade |
NYU°° / Janssen |
| inotuzumab ozogamicine |
CD22 |
Besponsa |
Pfizer |
| ipilimumab. |
CTLA-4 |
Yervoy |
Medarex / Bristol-Myers Squibb |
| isatuximab |
CD38 |
- |
Sanofi |
| iscalimab |
CD40 |
- |
Xoma / Novartis |
| ixékizumab |
IL-17A |
Taltz |
Eli Lilly & Company |
| lacnotuzumab |
CSF-R (CD115) |
- |
Novartis |
| lanadélumab |
kallicréine |
Takhzyro |
Takeda / Shire |
| larcaviximab |
Gp surface Ebola virus |
ZMapp |
Mapp Biopharmaceuticals |
| lenvervimab |
Ag HBs§
|
- |
GC Pharma |
| léronlimab |
CCR5 |
- |
CytoDyn |
| lexatumumab |
TRAIL-R2(DR5, APO-2) |
- |
Human Genome Sciences / Cambridge Antibody
Technology |
| ligélizumab |
IgE |
- |
Novartis |
| lirilumab |
KIR2DL1/L2/L3-
|
- |
Innate Pharma / Bristol-Myers Squibb |
| loncastuximab tésirine |
CD19 |
- |
ADC Therapeutics |
| lucatumumab |
CD40 |
- |
Chiron / Xoma / Novartis |
| lulizumab pégol |
CD28 |
- |
Bristol-Myers Squibb |
| lumiliximab |
CD23 (RFcεII) |
- |
Biogen Idec |
| mapatumumab |
TRAIL-R1 (DR4) |
- |
Human Genome Sciences (GlaxoSmith Kline)/ Cambridge
Antibody Technology (AstraZeneca) |
| magrolimab |
CD47 |
- |
Forty Seven Inc. |
| mirvétuximab soravtansine |
FOLR1 |
- |
ImmunoGen |
| mitazalimab |
CD40 |
- |
Alligator Biosciences / Janssen |
| modotuximab |
HER1 (ErbB-1) |
- |
Symphogen |
| mogamulizumab |
CCR4 |
Poteligeo |
BioWa / Kyowa Hakko Kirin Pharma |
| monalizumab |
CD94/NKG2A |
- |
Innate Pharma / AstraZeneca |
| mosunétuzumab |
CD20 x CD3e |
- |
Genentech (Roche) |
| motavizumab |
F(protéine de fusion) |
Numax |
MedImmune (AstraZeneca) |
| moxétumomab pasudotox |
CD22 |
Lumoxiti |
AstraZeneca / Innate Pharma |
| muromonab |
CD3ε |
Orthoclone OKT3 |
Janssen-Cilag |
| naptumomab estéfénatox |
5T4°°°°° |
- |
Active Biotech |
| natalizumab |
α4β1(VLA-4$) |
Tysabri |
Biogen / Élan |
| nécitumumab |
EGFR |
Portrazza |
Eli Lilly & Company |
| niversimab |
F(protéine de fusion) |
- |
MedImmune (AstraZeneca)Sanofi Pasteur |
| nivolumab |
PD-1 |
Opdivo |
Medarex / Bristol-Myers Squibb |
| obiltoxaximab |
PA# exotoxine(Anthrax) |
Anthim |
Elusys Therapeutics |
| obinutuzumab |
CD20 |
Gazyvaro / Gazyva |
Glycart Biotechnology (Roche) |
| ocrélizumab |
CD20 |
Ocrevus |
Roche |
| ofatumumab |
CD20 |
Arzerra |
Genmab / GlaxoSmithKline |
| omalizumab |
IgE |
Xolair |
Novartis |
| oportuzumab monatox |
EpCAM |
Vicinium |
Viventia Bio |
| otélixizumab |
CD3 |
- |
Tolerx / GlaxoSmithKline |
| otilimab |
GM-CSF |
- |
Morphosys / GlaxoSmithKline |
| oxélumab |
Ox40L (CD223) |
- |
Genentech (Roche) |
| pagibaximab |
Acide lipotéichoïque$$$
|
- |
Biosynexus |
| palivizumab |
VRS+++
|
Synagis |
MedImmune (AstraZeneca) |
| panitumumab |
EGFR |
|
|
| patéclizumab |
Lymphotoxine-α |
- |
Genentech (Roche) |
| pembrolizumab |
PD-1 |
Keytruda |
Merck Sharp and Dohme |
| pertuzumab |
HER2/neu |
Perjeta |
Genentech (Roche) |
| pexélizumab |
C5 |
- |
Alexion Pharmaceuticals |
| pidilizumab |
PD-1 (CD279) |
- |
Medivation |
| polatuzumab védotine-piqq |
CD79b |
Polivy |
Genentech (Roche) |
| porgaviximab |
Gp de surface |
ZMapp |
Mapp Biopharmaceutical / Public Health Agency of
Canada |
| prézalizumab |
ICOS-L (CD275) |
- |
Amgen |
| ramucirumab |
VEGF-R2 (KDR) |
Cyramza |
Eli Lilly & Company |
| ranibizumab |
VEGF-A |
Lucentis |
Genentech (Roche) / Novartis |
| ravagalimab |
CD40 |
- |
AbbVie |
| ravulizumab |
C5 |
Ultomiris |
Alexion Pharmaceuticals |
| raxibacumab |
PA exotoxine(Anthrax) |
ABthrax |
Human Genome Sciences / GlaxoSmithKline |
| rélatlimab |
LAG-3 (CD223) |
- |
Bristol-Myers Squibb |
| risankizumab |
IL-23Rp19 |
- |
Boehringer Ingelheim / AbbVie |
| rituximab |
CD20 |
Rituxan/Mabthera |
Genentech (Roche) |
| rolédumab |
Rhésus D |
- |
LFB° Group |
| rontalizumab |
IFN-α |
- |
Genentech / Chugai Pharmaceuticals |
| rovalpituzumab tésirine |
DLL3###
|
Rova-T |
Stemcentrx / Abbvie |
| rovélizumab |
CD18 |
- |
Icos Corp. (Eli Lilly & Company) |
| ruplizumab |
CD40L (CD154) |
Antova |
Biogen |
| sacituzumab govitécan |
Trop-2 |
- |
Immunomedics |
| sarilumab |
IL-6Rα (CD126) |
Kevzara |
Regeneron / Sanofi Aventis |
| sécukinumab |
IL-17A |
Cosentyx |
Novartis |
| sélicrélumab |
CD40 |
- |
Roche |
| sévirumab |
gH###
|
- |
PDL BioPharma / Novartis |
| sibrotuzumab |
Fibroblastactivation protein (FAP) |
- |
Boehringer Ingelheim Pharma |
| sintilimab |
PD-1 (CD279) |
Tyvit |
Innovent Biologics / Eli Lilly and Co |
| spartalizumab |
PD-1 (CD279) |
- |
Novartis |
| suptavumab |
F(protéine de fusion) |
- |
Regeneron Pharmaceuticals |
| suvratoxumab |
Staphylococcus aureus alpha toxin |
- |
MedImmune (AstraZeneca) |
| tavolimab |
OX-40 (CD134) |
- |
MedImmune (AstraZeneca) |
| téfibazumab |
ClfA####
|
Aurexis |
Inhibitex (Bristol-Myers Squibb) |
| ténéliximab |
CD40 |
- |
? |
| téplizumab |
CD3 |
- |
ProventionBio |
| théralizumab |
CD28 |
- |
TeGenero Immuno Therapeutics / TheraMAB |
| tigatuzumab |
TRAIL-R2(DR5, APO-2) |
- |
Daiichi Sankyo |
| tiragolumab |
TIGIT |
- |
Genentech (Roche) |
| tislélizumab |
PD-1 (CD279) |
- |
Beigene / Celgene (Bristol-Myers Squibb) |
| tocilizumab |
IL-6Rα (CD126) |
Actemra/RoActemra |
Chugai (Roche) |
| toralizumab |
CD40L (CD154) |
- |
Idec Pharmaceuticals |
| toripalimab |
PD-1 (CD279) |
- |
Shanghai Junshi Bioscience Co |
| tositumomab |
CD20 |
Bexxar |
GlaxoSmithKline |
| trastuzumab |
HER2/neu |
Herceptine |
Genentech / Roche |
| trastuzumab déruxtécan |
HER2/neu |
- |
Daiichi Sankyo |
| trastuzumab duocarmazine |
HER2/neu |
- |
Synthon Biopharmaceuticals BV |
| trémélimumab |
CTLA-4 (CD152) |
- |
Pfizer / Medimmune LLCAstraZeneca |
| ublituximab |
CD20 |
- |
LFB° Group / TG Therapeutics |
| urélumab |
4-1BB (CD137) |
- |
Bristol-Myers Squibb |
| ustékinumab |
IL-23Rp40 |
Stelara |
Janssen |
| utomilumab |
4-1BB (CD137) |
- |
Pfizer |
| vanalimab |
CD40 |
- |
Alligator BioScience /Janssen Biotech |
| varlilumab |
CD27 |
- |
Celldex therapeutics |
| védolizumab |
α4β7 |
Entyvio |
Takeda |
| veltuzumab |
CD20 |
- |
Immunomedics |
| volociximab |
α5β1 |
- |
PDL BioPharma / Biogen Idec |
| vopratélimab |
ICOS (CD278) |
- |
Jounce Therapeutics |
